ST. PAUL, Minn., April 8, 2019 /PRNewswire/ — IGF Oncology, LLC, a clinical-stage biotech company developing targeted anti-cancer therapies with better efficacy and lower side effects compared to existing chemotherapy treatments, today named Gary G. Altman, Ph.D., as its new Chief Executive Officer in an announcement made by Company Founder and President Hugh McTavish, Ph.D.
Prior to IGF Oncology, Altman served as CEO of Provista Diagnostics Inc. He also served in leadership roles at several public and private biotech and pharma companies including Human Longevity, Beckman Coulter, Terumo BCT, and Sequoia Pharmaceuticals.
“We are delighted to share the enthusiasm and vision that Dr. Altman, an accomplished business leader in medical diagnostics, therapeutics and life sciences, holds for the advancements IGF Oncology is making,” said Dr. McTavish. “His leadership, building from development-stage to commercial experience will be instrumental in advancing IGF Oncology’s lead product, IGF-MTX, which targets Myelodysplastic syndrome (MDS), a deadly blood cancer, and acts without decreasing patients’ blood cells. I look forward to working with Dr. Altman and strengthen our pipeline into new indications.”
“IGF Oncology has the potential of becoming a leader in oncology therapeutics,” said Dr. Altman. “The basis of our current technology employs therapeutic conjugates targeting the IGF-1 receptor which is over-expressed on certain cancer cells and is increasingly over-expressed in more aggressive cancers. Our lead drug candidate, now in clinical trials, has provided preliminary evidence of improved efficacy and reduced associated toxicities. I look forward to our developing additional novel therapeutics, advancing our ongoing clinical trial, and leading the company to commercial success.”
Dr. Altman received his B.S. in Microbiology and Chemistry from Georgia State University, his M.S. from Georgia Institute of Technology where he was also a NASA Fellow, a Ph.D. in Virology and Biochemistry from Western University where he was also a NIH Pre-Doctoral Fellow. He was a NIH Post-Doctoral Fellow at the Biophysics Institute and McCardle Cancer Research Laboratory at the University of Wisconsin-Madison. Dr. Altman also served on the MBA faculty at Johns Hopkins University.
About IGF Oncology
IGF Oncology, LLC is a clinical-stage biotech company developing targeted anti-cancer therapies with better efficacy and lower side effects compared to existing chemotherapy treatments. The Company’s lead product, IGF-MTX, is a conjugate of the drug methotrexate and a proprietary recombinant protein derivative of insulin-like growth factor-1 (IGF-1), the receptor for which is overexpressed by a number of cancers. A clinical study showed that IGF-MTX was effective at a concentration 12-fold lower than the lowest prescribed dose of methotrexate, across multiple tumor types, and without the dose-limiting side effect of cytopenia. The Company is currently conducting a Phase 1b/2a study with the Mayo Clinic in patients with Myelodysplastic syndrome (MDS) and raising additional capital to fund this asset through potential approval.
Tiberend Strategic Advisors, Inc.
Brian Pinkston (Investors)
David Schemelia (Media)
SOURCE IGF Oncology